Mecanismos epigenéticos en la diferenciación eritroide y linfoideel regulador transcripcional CTCF y fármacos epigenéticos
- GARCIA GAIPO, LORENA
- Javier León Serrano Director
- María Dolores Delgado Villar Co-director
Defence university: Universidad de Cantabria
Fecha de defensa: 13 December 2019
- José Carlos Díez Ballesteros Chair
- Flor María Pérez Campo Secretary
- Veronica Torrano Moya Committee member
Type: Thesis
Abstract
CTCF transcription factor can interact with a high number of DNA sequences and is involved in the regulation of gene transcription, chromatin insulation, epigenetic regulation and genome organization. Previous results of our group indicated a possible role of CTCF in the regulation of erythroid differentiation. Our results indicate that CTCF downregulation inhibits erythropoiesis through the regulation of erythroid specific genes in human hematopoietic cells. In contrast to genetic alterations, epigenetic modifications are potentially reversible and can be targeted with specific epigenetic drugs. Therapy with epigenetic drugs has an enormous potential in lymphoma-8 treatment. Combination treatment with romidepsin (HDAC inhibitor) and JQ1 (BET bromodomain inhibitor) synergistically induces apoptosis, cell cycle arrest and plasma cell differentiation. These results suggest a potential role for the treatment of aggressive 8-cell lymphomas.